Compare Citius Pharmaceuticals Inc (CTXR) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Iron Mountain Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Iron Mountain Inc trades at $122.75 (market cap $36.19B). The key difference: Iron Mountain Inc is far larger — about 1932.2× Citius Pharmaceuticals Inc's market cap, and Iron Mountain Inc pays a 2.84% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | IRM | |
|---|---|---|
Market Cap | $18.73M | $36.19B |
Sector | Health | Real Estate |
52-Week High | $1.82 | $133.06 |
52-Week Low | $0.48 | $78.86 |
Enterprise Value | $14.95M | $55.60B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Iron Mountain (IRM) trades at $121.15, down 0.66% on the day, amid a bearish technical signal. The company reported strong Q2 2026 results with revenue up 19% year-over-year to $2.03 billion, beating estimates, and has a consensus analyst price target of $141.50. However, high debt levels and a negative shareholder equity position present fundamental concerns.
Outlook is mixed: robust data center and digital growth support upside, but elevated valuation ratios and rising debt-to-asset ratios pose risks. Analyst sentiment is predominantly buy-rated (65%), yet technical indicators suggest near-term caution. Investors should weigh strong operational performance against financial leverage and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
